Jessie Torgersen - Faculty Biosketch

Jessie Torgersen, MD, MHS, MSCE

Assistant Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania

Attending Physician, Penn Presbyterian Medical Center

Director, Center for Viral Hepatitis, Penn Presbyterian Medical Center

Senior Scholar , Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine

Director, Penn Medicine Hepatitis Linkage Team

Department: Medicine

Contact information

Division of Infectious Diseases
Medical Arts Building, Suite 103A
Penn Presbyterian Medical Center
Philadelphia, PA 19104

Office: 215-662-9908
Fax: 215-243-4658

Links
Lo Re Research Group
AASLD/IDSA Recommendations for Testing, Managing, and Treating Hepatitis C

Education:
BS (Microbiology)
University of California, Santa Barbara, 2002.
BA (Physical Anthropology)
University of California, Santa Barbara, 2002.
MHS (Epidemiology)
Johns Hopkins Bloomberg School of Public Health, 2005.
MD
Wayne State University School of Medicine, 2010.
MSCE
University of Pennsylvania Perelman School of Medicine, 2018.
Cert (Biomedical Informatics)
University of Pennsylvania Perelman School of Medicine, 2025.

Post-Graduate Training
Intern in Medicine, Emory University School of Medicine, Atlanta, GA, 2010-2011.
Resident in Medicine, Emory University School of Medicine, Atlanta, GA , 2011-2013.
Fellow in Infectious Diseases, Hospital of the University of Pennsylvania, 2013-2015.
NRSA Postdoctoral Fellow, Infectious Diseases, University of Pennsylvania Perelman School of Medicine , 2015-2016.
Postdoctoral Fellow, Infectious Diseases, University of Pennsylvania Perelman School of Medicine, 2016-2018.

Certifications
Diplomate, American Board of Internal Medicine, 2013.
Diplomate Infectious Diseases, American Board of Internal Medicine, 2016.

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Clinical Expertise

HIV and chronic liver disease, including hepatitis B, hepatitis C, and fatty liver disease.

Description of Research Expertise

Epidemiology and clinical impact of liver disease in HIV, specifically hepatic steatosis, viral hepatitis and hepatocellular carcinoma in HIV

Selected Publications

Mehta SJ, Torgersen J, Small DS, Mallozzi CP, McGreevey III JD, Rareshide CAL, Evans CN, Epps M, Stabile D, Snider CK, Patel MS.: Effect of a Default Order vs an Alert in the Electronic Health Record on Hepatitis C Virus Screening Among Hospitalized Patients: A Stepped-Wedge Randomized Clinical Trial. JAMA Network Open 5(3): e222427, March 2022.

Torgersen J, Taddei TH, Lo Re V 3rd.: Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?" Journal of Hepatology March 2022.

Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re III V: Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal of Hepatology 75(6): 1312-1322, December 2021.

Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd; North American AIDS Cohort Collaboration on Research, Design of IeDEA.: Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. Hepatology 74(3): 1190-1202, September 2021.

Anand P, Wilson J, Carter B, Bronstein A, Schwartz A, Harrington B, Adams T, Saine ME, Norris A, Metzger D, Short WR, Torgersen J.: Clinic screening for adverse childhood experiences in people living with HIV to Improve Care Delivery. AIDS Care 22(1): 1-9, July 2021.

Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V 3rd.: Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. J Acquir Immune Defic Syndr 85(5): 530-534, December 2020.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, de Castilla DL, Finberg KW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group : Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 383(19): 1813-1826, November 2020.

Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Lo Re III V: HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. J Natl Cancer Inst 112(7): 747-755, July 2020.

Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Mitchell Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Lo Re V 3rd.: Differences in Pathology, Staging, and Treatment between HIV(+) and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev 29(1): 71-78, January 2020.

Torgersen J, So-Armah K, Freiberg MS, Goetz MB, Budoff MJ, Lim JK, Taddei T, Butt AA, Rodriguez-Barradas MC, Justice AC, Kostman JR, Lo Re V 3rd.: Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. BMC Gastroenterol 19(1): 52, April 2019.

Torgersen J, Bellamy SL, Ratshaa B, Han X, Mosepele M, Zuppa AF, Vujkovic M, Steenhoff AP, Bisson GP, Gross R: Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans. European Journal of Drug Metabolism and Pharmacokinetics 44(2): 179-187, April 2019.